| PORACTANT ALPHA
Classifications: lung surfactant; Therapeutic: lung surfactant
120 mg/1.5 mL, 240 mg/3 mL vials
Lung surfactant obtained from minced porcine lungs. Endogenous pulmonary surfactant lowers the surface tension on alveoli
surfaces during respiration, and stabilizes the alveoli against collapse at resting pressures.
Alleviates respiratory distress syndrome (RDS) in premature infants caused by deficiency of surfactant.
Treatment (rescue) of respiratory distress syndrome in premature infants.
Hypersensitivity to porcine products or poractant alpha.
Infants born >3 wk after ruptured membranes; intraventricular hemorrhage of grade III or IV; major congenital malformations;
nosocomial infection; pretreatment of hypothermia or acidosis due to increased risk of intracranial hemorrhage; lactation.
Route & Dosage
|Respiratory Distress Syndrome
Neonate: Intratracheal 2.5 mL/kg birth weight, may repeat with 1.25 mL/kg q12h x 2 more doses if needed (max: 5 mL/kg)
Note: Correction of acidosis, hypotension, anemia, hypoglycemia, and hypothermia is recommended prior to administration of poractant
- Warm vial slowly to room temperature; gently turn upside down to form uniform suspension, but do NOT shake.
- Withdraw slowly the entire contents of a vial (concentration equals 80 mg/mL) into a 3 or 5 mL syringe through a large gauge
(>20 gauge) needle.
- Attach a 5 French catheter, precut to 8 cm, to the syringe.
- Fill the catheter with poractant alfa and discard excess through the catheter so that only the total dose to be given remains
in the syringe.
- Refer to specific instruction provided by manufacturer for proper dosing technique. Follow instructions carefully regarding
installation of drug and ventilation of infant. Note that catheter tip should not extend beyond distal tip of endotracheal
- Store refrigerated at 2°8° C (36°46° F) and protect from light. Do not shake vials. Do not
warm to room temperature and return to refrigeration more than once.
Adverse Effects (≥1%) CV:
Bradycardia, hypotension. Respiratory:
Intratracheal tube blockage, oxygen desaturation.
Assessment & Drug Effects
- Stop administration of poractant alfa and take appropriate measures if any of the following occur: Transient episodes of
bradycardia, decreased oxygen saturation, reflux of poractant alfa into endotracheal tube, or airway obstruction. Dosing
may resume after stabilization.
- Do not suction airway for 1 h after poractant alfa instillation unless there is significant airway obstruction.